Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

• Main Authors: Vergnenègre A (Author), Ray JA (Author), Chouaid C (Author), Grossi F (Author), Bischoff HG (Author), Heigener DF (Author), Walzer S (Author)
• Formato: Livro
• Publicado em: Dove Medical Press, 2012-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Alain Vergnenègre1, Joshua A Ray2, Christos Chouaid3, Francesco Grossi4, Helge G Bischoff5, David F Heigener6, Stefan Walzer21Department of Pneumology, Hôpital du Cluzeau, Limoges, France; 2Global Health Economics and Strategic Pricing, F Hoffmann-La Roche Ltd, Basel, Switzerlan...